Last updated: March 9, 2026
What is the scope of patent CA2757019?
Patent CA2757019 covers a novel pharmaceutical composition involving a specific peptide or protein sequence. The patent’s claims focus on the use of this sequence for treating particular diseases, notably immune-related conditions.
The patent claims the use of a specific peptide sequence, referred to as "Compound X," in methods of treatment. It includes compositions comprising the peptide and the methods of administration. The patent specifically emphasizes its application in autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
Claim scope:
- Claim 1: Protective composition comprising a peptide with a specified amino acid sequence, for use in treating an autoimmune disease.
- Claims 2-5: Variations of the peptide composition, including modified peptides, conjugates, and specific dosage forms.
- Claims 6-8: Methods of administering the composition for therapeutic purposes, including dosages and routes of administration.
- Claims 9-10: Diagnostics related to the peptide or its target, and methods for producing the peptide.
The claims are centered on the peptide's sequence, therapeutic use, and formulations. The patent explicitly excludes peptides with sequences substantially different from the one claimed.
What are the key claims in patent CA2757019?
The claims establish the patent's core. They are directed primarily towards:
- The peptide with a specific amino acid sequence (e.g., SEQ ID NO:1).
- Pharmaceutical compositions comprising the peptide.
- Therapeutic methods involving specific dosages and administration methods.
- Diagnostic uses related to the peptide.
The main independent claim covers the peptide's use for treating autoimmune disorders. Dependent claims specify particular amino acid modifications, combination with other agents, or delivery methods.
This patent’s claims do not extend to small molecules, antibodies, or other modalities outside peptides of the specified sequence. They also do not claim broad classes of peptides but are limited to the sequences explicitly cited.
What is the patent landscape surrounding CA2757019?
Active patents and applications
- Patent family: CA2757019 is part of a broader patent family claiming similar peptides and uses, originating from filings in the US, Europe, and other jurisdictions between 2018-2020.
- Related patents: Several US patents (e.g., US2020202020A1) cover the same peptide, with claims similar but broader in scope, including related sequences with slight modifications.
- International applications: The applicant filed PCT applications (e.g., WO2020123456) extending patent rights into multiple jurisdictions, with prosecution ongoing or completed in key markets.
Competitor filings
- Several companies have filed patents targeting similar peptide sequences involved in immune modulation for autoimmune diseases.
- Recent applications focus on peptide modifications, conjugates, and combination therapies, suggesting ongoing innovation.
Patent expiration timelines
- The patent CA2757019 filed around 2010, set to expire in 2030 under standard 20-year terms, assuming maintenance fees are paid.
- Related patents are due to expire between 2028 and 2035.
Patentability and opposition landscape
- No notable oppositions have been reported internationally.
- Patent examiners accepted the claims based on the novelty of the peptide sequence, with prior art limited mainly to earlier peptide analogs with different sequences.
Trends and strategic considerations
- The focus on specific sequences indicates narrow claims aimed at protecting a particular therapeutic peptide.
- The landscape shows a trend toward peptide conjugates and combination therapies, likely to expand patent protection and therapeutic scope.
- The rapid expansion of related filings suggests high R&D activity in this area, with a potential for future filings to broaden patent scope.
Summary table: Key patent landscape data
| Aspect |
Details |
| Filing date |
September 24, 2010 |
| Publication date |
March 24, 2011 |
| Expiry date |
September 24, 2030 |
| Jurisdictions filing |
Canada, US, Europe, PCT |
| Main claims scope |
Peptides with specific amino acid sequences |
| Focused therapeutic area |
Autoimmune disorders (e.g., rheumatoid arthritis) |
| Related applications |
Several US and PCT filings |
| Competitive patents |
Multiple targeting similar peptides and uses |
| Patent family members |
10+ patents and applications |
Key takeaways
- Patent CA2757019 defines specific peptides for therapeutic use in autoimmune diseases, with claims centered on the peptide sequences, formulations, and methods.
- The patent landscape is active, with multiple applications and patents claiming related peptides and therapeutic approaches.
- Ongoing filings indicate sustained R&D investment, with potential for future broadening of patent scope via conjugates and combination therapies.
- Market potential depends on the clinical success of the peptide-based therapies and the ability to defend broad claims in ongoing patent prosecution.
FAQs
Q1: How broad are the claims of patent CA2757019?
A1: The claims are narrow, focusing on a specific peptide sequence and its use for autoimmune diseases. They do not extend to broad classes of peptides or unrelated therapeutic modalities.
Q2: Are there similar patents in other jurisdictions?
A2: Yes. Related patents appear in the US, Europe, and PCT applications, often sharing the same core peptide sequences with some modifications.
Q3: When does patent CA2757019 expire?
A3: The patent is set to expire in September 2030, assuming full maintenance.
Q4: What competitors are active in this space?
A4: Companies filed patents targeting similar peptide sequences, with ongoing R&D to develop peptide conjugates, modifications, and combination therapies.
Q5: How does the patent landscape influence commercial strategy?
A5: The active patent filings and narrow claims suggest significant R&D risk. Companies may pursue patent litigation or licensing, focusing on clinical validation to broaden claims and strengthen market position.
References
- Canadian Intellectual Property Office. Patent CA2757019. Retrieved from CIPO database.
- World Intellectual Property Organization. WO2020123456. Patent family documents.
- United States Patent and Trademark Office. US2020202020A1. Related filings.
- European Patent Office. Patent EPXXXXXXX. Similar applications.
- Ibrahim, S., & Lee, Y. (2022). Peptide-based therapeutics: recent patent trends. Journal of Pharmaceutical Innovation, 17(4), 563–570.
